Eirion Therapeutics Unveils Promising AI-09 Liquid Botulinum Trial Results at 2025 SID Meeting

AI-09 is a novel liquid comprised of a botulinum nanoemulsion–an active botulinum molecule encapsulated in a “nano-sized” droplet of oil for the treatment of glabellar lines.
AI-09 is a novel liquid comprised of a botulinum nanoemulsion–an active botulinum molecule encapsulated in a “nano-sized” droplet of oil for the treatment of glabellar lines.
Courtesy of Prostock-studio at Adobe Stock

At the 2025 annual meeting of the Society for Investigative Dermatology that took place in San Diego, California on May 7-10, Eirion Therapeutics Inc., a biopharmaceutical company, presented results from recent clinical trials evaluating its AI-09—a novel liquid comprised of a botulinum nanoemulsion, an active botulinum molecule encapsulated in a “nano-sized” droplet of oil for the treatment of glabellar lines.

Log in to view the full article
More in Companies